150
Participants
Start Date
April 30, 2009
Primary Completion Date
October 31, 2012
Study Completion Date
January 31, 2013
ALT-836
In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
Placebo
In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
Mount Sinai Medical Center, New York
Memorial Sloan-Kettering Cancer Center, New York
Wake Forest University, Winston-Salem
Piedmont Respiratory Research Foundation, Greensboro
Carolinas Medical Center, Charlotte
University of Louisville-Division of Pulmonary and Critical Care, Louisville
Kentucky Lung Clinic, Hazard
University of Iowa, Iowa City
West Suburban Hospital Medical Center, Oak Park
Northwestern University, Chicago
Illinois Lung and Critical Care Institute, Peoria
Saint Louis University, St Louis
Mercy Hospital St. Louis, St Louis
Saint Luke's Hospital, Kansas City
University of Oklahoma, Oklahoma City
Los Angeles County and USC Medical Center, Los Angeles
Stanford University, Stanford
UC Davis Medical Center, Sacramento
Yale University, New Haven
Baystate Medical Center, Springfield
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Altor BioScience
INDUSTRY